The possible role of insulin-like growth factor-1 in osteosarcoma

Li, Yu-sheng; Liu, Qing; He, Hong-bo; Luo, Wei

doi:10.1016/j.currproblcancer.2018.08.008

Cited by 35Growth Hormone and Insulin-like Growth FactorsSarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

The possible role of insulin-like growth factor-1 in osteosarcoma

Li, Yu-sheng, Liu, Qing, He, Hong-bo, Luo, Wei·2019·Current Problems in Cancer

DOI 10.1016/j.currproblcancer.2018.08.008

Open this paper in CoChat — free account

Abstract

Osteosarcoma (OS) is a common malignant tumor of bone, of which clear understanding of molecular pathologic process is not yet possible. Insulin-like growth factor-1 (IGF-1) is a hormone that plays vital role in development and function of many tissues. Unfortunately, IGF-1 and its receptor (IGF-1R)'s over-expression have been implicated in carcinogenesis, and indicated to constitute a risk factor for the development of multiple human cancers, including OS. Increased levels of IGF-1 and IGF-1R have been reported in OS, leading to cancer progression through transformation, proliferation, pro-metastasis, and decreased susceptibility to apoptosis. Over-expression of IGF-1/IGF-1R signaling also contributes to tumor cell survival, metastasis, and resistance to chemotherapeutic drugs. IGF-1 has been included as an OS marker recently, and targeting IGF-1 is an interesting and promising approach in OS therapeutics. However more investigations with clinical trials are necessary to validate the use of drugs against IGF-1 that may provide a basis for new therapeutic approaches to treat this devastating disease. This review article focused on the role of IGF-1/IGF-1R in OS progression and therapeutic aspects of OS targeting IGF-1.

Integrity signals

Registry

Crossref · 10.1016/j.currproblcancer.2018.08.008

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osteosarcoma tumours arise during puberty, when many progenitor cells undergo differentiation in response to signalling via FGF2, RANKL and IGF1.
“Osteosarcoma tumours arise during puberty, when many progenitor cells undergo differentiation in response to signalling via, for example, FGF2 (ref.96 ), RANKL 96,97 and IGF1 (ref.98 ).”
From Osteosarcoma (2022) · cites this paper as [98]
IGF1 receptor amplifications occur in up to 14% of patients with osteosarcoma and seem to drive activation of the PI3K-AKT-mTOR pathway through the MAPK pathway.
“Indeed, IGF1 receptor amplifications occur in up to 14% of patients with osteosarcoma 38 , which seems to drive activation of the PI3K-AKT-mTOR pathway through the MAPK pathway 98 .”
From Osteosarcoma (2022) · cites this paper as [98]

1 retracted

MicroRNA-503 suppresses cell proliferation and invasion in osteosarcoma via targeting insulin-like growth factor 1 receptor
Wang, Z., Zheng, C., Jiang, K., He, J., Cao, X., & Song, W. C. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4648 · Cited by 19 · see citing works
Retracted
The Epidemiology of Osteosarcoma
Ottaviani, G., & Jaffe, N. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_1 · Cited by 1,793 · see citing works
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S., Meltzer, P. S., & Gorlick, R. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,578 · see citing works
Insulin-like growth factors and cancer
Fürstenberger, G., & Senn, H.-J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00731-3 · Cited by 538 · see citing works
Osteosarcoma Overview
Lindsey, B. A., Markel, J., & Kleinerman, E. S. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 490 · see citing works
The role of the insulin-like growth factor-1 system in breast cancer
CHRISTOPOULOS, P. F., Msaouel, P., & Koutsilieris, M. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0291-7 · Cited by 377 · see citing works
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D., & LeRoith, D. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0374 · Cited by 303 · see citing works
Molecular mechanisms of chemoresistance in osteosarcoma (Review)
He, H., Ni, J., & Huang, J. X. (2014) · Oncology Letters · doi:10.3892/ol.2014.1935 · Cited by 234 · see citing works
Self-citation
The Etiology of Osteosarcoma
Ottaviani, G., & Jaffe, N. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_2 · Cited by 232 · see citing works
Bone microenvironment signals in osteosarcoma development
Alfranca, A., Martínez-Cruzado, L., Tornín, J., Abarrategi, A., Amaral, A. T., de Álava, E., Menéndez, P. R., Garcı́a-Castro, J., & Rodrı́guez, R. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1918-y · Cited by 224 · see citing works
Osteosarcoma: Cells‐of‐Origin, Cancer Stem Cells, and Targeted Therapies
Abarrategi, A., Tornín, J., Martínez-Cruzado, L., Hamilton, A., Martínez‐Campos, E., Rodrigo, J. P., González, M. V., Baldini, N., Garcı́a-Castro, J., & Rodrı́guez, R. (2016) · Stem Cells International · doi:10.1155/2016/3631764 · Cited by 211 · see citing works
Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade
Iams, W. T., & Lovly, C. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2518 · Cited by 178 · see citing works
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group
Weigel, B. J., Malempati, S., Reid, J. M., Voss, S. D., Cho, S. Y., Chen, H. X., Krailo, M., Villaluna, D., Adamson, P. C., & Blaney, S. M. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24605 · Cited by 161 · see citing works
Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma
Scotlandi, K., Manara, M. C., Hattinger, C. M., Benini, S., Perdichizzi, S., Pasello, M., Bacci, G., Zanella, L., Bertoni, F., Picci, P., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.015 · Cited by 132 · see citing works
IGF‐1 receptor contributes to the malignant phenotype in human and canine osteosarcoma
MacEwen, E. G., Pastor, J., Kutzke, J., Tsan, R. Z., Kurzman, I. D., Thamm, D. H., Wilson, M., & Radinsky, R. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20046 · Cited by 118 · see citing works
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas
Asmane, I., Watkin, E., Alberti, L., Duc, A., Marec‐Bérard, P., Ray-Coquard, I. L., Cassier, P. A., Decouvelaere, A., Ranchère‐Vince, D., Kurtz, J., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.009 · Cited by 115 · see citing works
Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma
Evola, G., Costarella, L., Pavone, V., Caff, G., Cannavò, L., Sessa, A., Avondo, S., & Sessa, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00150 · Cited by 107 · see citing works
Long non-coding RNAs in osteosarcoma
Chen, R., Wang, G., Zheng, Y., Hua, Y., & Cai, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.14726 · Cited by 92 · see citing works
At-Risk Populations for Osteosarcoma: The Syndromes and Beyond
Calvert, G. T., Randall, R. L., Jones, K. B., Cannon-Albright, L., Lessnick, S., & Schiffman, J. D. (2012) · Sarcoma · doi:10.1155/2012/152382 · Cited by 90 · see citing works
Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
Duan, Z., Choy, E., Harmon, D. C., Cao, Y., Ryu, K., Schwab, J. H., Mankin, H. J., & Hornicek, F. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0115 · Cited by 84 · see citing works
Increased expression of insulin‐like growth factor‐1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma
Wang, Y., Han, X., Qiu, Y., Xiong, J., Yu, Y., Wang, B., Zhu, Z., Qian, B., Chen, Y., Wang, S., et al. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22077 · Cited by 83 · see citing works
Cross-Talk between Adiponectin and IGF-IR in Breast Cancer
Mauro, L., Naimo, G. D., Ricchio, E., Panno, M. L., & Andò, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00157 · Cited by 67 · see citing works
Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells
Rozengurt, E. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00357 · Cited by 64 · see citing works
Involvement and Clinical Aspects of MicroRNA in Osteosarcoma
Kumar, R., Boro, A., & Fuchs, B. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060877 · Cited by 64 · see citing works
Epithelial–Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines
Zhao, H., Desai, V., Wang, J., Epstein, D. M., Miglarese, M. R., & Buck, E. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0327 · Cited by 61 · see citing works
MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion via Targeting IGF-1R
Chen, G., Fang, T., Huang, Z., Qi, Y., Du, S., Di, T., Lei, Z., Zhang, X., & Yan, W. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000438653 · Cited by 61 · see citing works
Dichotomy of decorin activity on the insulin‐like growth factor‐I system
Morrione, A., Neill, T., & Iozzo, R. V. (2013) · FEBS Journal · doi:10.1111/febs.12149 · Cited by 59 · see citing works
A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy.
Khanna, C., Prehn, J., Hayden, D. W., Cassaday, R. D., Caylor, J., Jacob, S. T., Bose, S., Hong, S. H., Hewitt, S. M., & Helman, L. J. (2002) · PubMed · Cited by 56 · see citing works
Treatment of Metastatic Osteosarcoma With the Somatostatin Analog OncoLar: Significant Reduction of Insulin-Like Growth Factor-1 Serum Levels
Mansky, P. J., Liewehr, D. J., Steinberg, S. M., Chrousos, G. P., Avila, N. A., Long, L., Bernstein, D. B., Mackall, C. L., Hawkins, D. S., & Helman, L. J. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200208000-00007 · Cited by 55 · see citing works
mTOR: An attractive therapeutic target for osteosarcoma?
Liu, D., Congwei, L., Qing, B., Yang, T., Ruiguo, W., Yu, H., Bo, D., & Li, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.9305 · Cited by 55 · see citing works
Insulin-Like Growth Factor and Epidermal Growth Factor Signaling in Breast Cancer Cell Growth: Focus on Endocrine Resistant Disease
Voudouri, K., Berdiaki, A., Tzardi, M. N., Tzanakakis, G. N., & Nikitovic, D. (2015) · Analytical Cellular Pathology · doi:10.1155/2015/975495 · Cited by 52 · see citing works
Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma
Cao, Y., Roth, M. E., Piperdi, S., Montoya, K., Sowers, R. S., Rao, P. H., Geller, D., Houghton, P. J., Kolb, E. A., Gill, J. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106249 · Cited by 45 · see citing works
Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells
Wang, Y., Wang, Z.-X., Qiu, Y., Xiong, J., Chen, Y., Miao, D., & De, W. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0064-y · Cited by 45 · see citing works
Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma
Maniscalco, L., Iussich, S., Morello, E. M., Martano, M., Gattino, F., Miretti, S., BIOLATTI, B., Accornero, P., Martignani, E., Sánchez‐Céspedes, R., et al. (2014) · The Veterinary Journal · doi:10.1016/j.tvjl.2014.09.005 · Cited by 40 · see citing works
Increase in insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 after supplementation with selenium and coenzyme Q10. A prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens
Alehagen, U., Johansson, P., Aaseth, J., Alexander, J., & Brismar, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178614 · Cited by 40 · see citing works
MicroRNA-26a inhibits osteosarcoma cell proliferation by targeting IGF-1
Tan, X., Fan, S., Wu, W., & Zhang, Y. (2015) · Bone Research · doi:10.1038/boneres.2015.33 · Cited by 35 · see citing works
Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo
Wang, Y., Xiong, J., Wang, S., Yu, Y., Wang, B., Chen, Y., Shi, H.-F., & Qiu, Y. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0453-2 · Cited by 33 · see citing works
Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray
Jentzsch, T., Robl, B., Husmann, M., Bode‐Lesniewska, B., & Fuchs, B. (2014) · PubMed · doi:10.5167/uzh-98588 · Cited by 31 · see citing works
MiR-100 Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion and Enhances Chemosensitivity by Targeting IGFIR
Liu, Y., Zhu, S., Wang, X., Deng, J., Li, W., Zhang, P., & Liu, B.-S. (2015) · Technology in Cancer Research & Treatment · doi:10.1177/1533034615601281 · Cited by 31 · see citing works
Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor
Davaadelger, B., Duan, L., Perez, R. E., Gitelis, S., & Maki, C. G. (2016) · Oncotarget · doi:10.18632/oncotarget.8484 · Cited by 31 · see citing works
Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung Cancer.
Nurwidya, F., Andarini, S., Takahashi, F., Syahruddin, E., & Takahashi, K. (2016) · Europe PMC (PubMed Central) · Cited by 28 · see citing works
Insulin-like Growth Factor I (IGF-I) Stimulates Proliferation but also Increases Caspase-3 Activity, Annexin-V Binding, and DNA-fragmentation in Human MG63 Osteosarcoma Cells: Co-activation of Pro- and Anti-apoptotic Pathways by IGF-I
Raile, K., Hille, R., Laue, S., Schulz, A., Pfeifer, G. P., Horn, F., & Kiess, W. (2003) · Hormone and Metabolic Research · doi:10.1055/s-2004-814140 · Cited by 24 · see citing works
Chimaphilin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines through insulin-like growth factor-I receptor (IGF-IR) signaling
Daqian, W., Wang, C., Xinhua, Q., Ai, S., & Kerong, D. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.05.008 · Cited by 23 · see citing works
The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor
Yang, J. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1071 · Cited by 23 · see citing works
Inhibition of insulin-like growth factor receptor: end of a targeted therapy?
Pillai, R. N., & Ramalingam, S. S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.11.05 · Cited by 21 · see citing works
Alteration of the insulin‐like growth factor axis during in vitro differentiation of the human osteosarcoma cell line HOS 58
Viereck, V., Siggelkow, H., Pannem, R., Braulke, T., Scharf, J., & Kübler, B. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21274 · Cited by 21 · see citing works
Comparative Outcome of Thai Pediatric Osteosarcoma Treated with Two Protocols: the Role of High-Dose Methotrexate (HDMTX) in a Single Institute Experience
Choeyprasert, W., Pakakasama, S., Sirachainan, N., Songdej, D., Chuansumrit, A., Anurathapan, U., Hongeng, S., & Nartthanarung, A. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.22.9823 · Cited by 19 · see citing works
Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin‐like growth factor I
Hong, S., Briggs, J., Newman, R. J., Hoffman, K. E., Mendoza, A., LeRoith, D., Helman, L. J., Yakar, S., & Khanna, C. (2008) · International Journal of Cancer · doi:10.1002/ijc.24169 · Cited by 18 · see citing works
Analysis of serum insulin growth factor‐1 concentrations in localized osteosarcoma: A children's oncology group study
Borinstein, S. C., Barkauskas, D. A., Bernstein, M. L., Goorin, A. M., Gorlick, R. G., Krailo, M., Schwartz, C. L., Wexler, L. H., & Toretsky, J. A. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24778 · Cited by 12 · see citing works
Insulin‐like growth factor 1 receptor inhibitors: Where do we come from? What are we? Where are we going?
Chmielowski, B. (2014) · Cancer · doi:10.1002/cncr.28727 · Cited by 8 · see citing works
Immuno-Oncology Integrative Networks: Elucidating the Influences of Osteosarcoma Phenotypes
Sharma, A., & Capobianco, E. (2017) · Cancer Informatics · doi:10.1177/1176935117721691 · Cited by 5 · see citing works

Flagged first, then by citations

4 of the 55 references couldn’t be matched to a known paper.

Sorted by citations

Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works
Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy
Zhao, J., Dean, D. C., Hornicek, F. J., Yu, X., & Duan, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.020 · Cited by 90 · see citing works
Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Tian, Z., Niu, X., & Yao, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01642 · Cited by 87 · see citing works
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Gazouli, I., Kyriazoglou, A., Kotsantis, I., Anastasiou, M., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Kontogeorgakos, V., et al. (2021) · Cancers · doi:10.3390/cancers13081757 · Cited by 63 · see citing works
Genomics and the Immune Landscape of Osteosarcoma
Wu, C.-C., & Livingston, J. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_2 · Cited by 58 · see citing works
Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma
Molina, E. R., Chim, L. K., Salazar, M. C., Mehta, S. M., Menegaz, B. A., Lamhamedi-Cherradi, S.-E., Satish, T., Mohiuddin, S., McCall, D. C., Zaske, A. M., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.029 · Cited by 47 · see citing works
IGF signaling pathway in bone and cartilage development, homeostasis, and disease
Ruan, X., Jin, X., Sun, F., Pi, J., Jinghu, Y., Lin, X., Zhang, N., & Chen, G. (2024) · The FASEB Journal · doi:10.1096/fj.202401298r · Cited by 37 · see citing works
The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis
Tzanakakis, G. N., Giatagana, E.-M., Berdiaki, A., Spyridaki, I., Hida, K., Neagu, M. T., Tsatsakis, A. M., & Nikitovic, D. (2021) · Cancers · doi:10.3390/cancers13102478 · Cited by 37 · see citing works
Immune classification of osteosarcoma
Le, T., Department of Mathematics and Statistics, U. O. M. A., Su, S., & Shahriyari, L. (2021) · Mathematical Biosciences and Engineering · doi:10.3934/mbe.2021098 · Cited by 35 · see citing works
Pan-Cancer Analysis of IGF-1 and IGF-1R as Potential Prognostic Biomarkers and Immunotherapy Targets
Zhang, Y., Gao, C., Cao, F., Wu, Y., Chen, S., Han, X., Mo, J., Qiu, Z., Fan, W., Zhou, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.755341 · Cited by 30 · see citing works
Exercise and Physical Activity in Patients with Osteosarcoma and Survivors
Garcia, M. B., Ness, K. K., & Schadler, K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_16 · Cited by 26 · see citing works
Effects of a root extract from Achyranthes Japonica Nakai on the growth performance, blood profile, fecal microbial community, fecal gas emission, and meat quality of finishing pigs
Dang, D. X., Kim, Y., & Kim, I. H. (2020) · Livestock Science · doi:10.1016/j.livsci.2020.104160 · Cited by 25 · see citing works
Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?
Hernández, I. B., Kromhout, J. Z., Teske, E., Hennink, W. E., van Nimwegen, S. A., & Oliveira, S. (2021) · Theranostics · doi:10.7150/thno.55760 · Cited by 23 · see citing works
Avenues of research in dietary interventions to target tumor metabolism in osteosarcoma
Leite, T. C., Watters, R. J., Weiss, K. R., & Intini, G. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03122-8 · Cited by 20 · see citing works
MicroRNA-939-5p directly targets IGF-1R to inhibit the aggressive phenotypes of osteosarcoma through deactivating the PI3K/Akt pathway
Zhao, X., Li, J., & Yu, D. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4333 · Cited by 19 · see citing works
Retracted
Alternative splicing of leptin receptor overlapping transcript in osteosarcoma
Rothzerg, E., Ho, X. D., Xu, J., Wood, D., Märtson, A., Maasalu, K., & Kõks, S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220949139 · Cited by 19 · see citing works
Novel application of single-cell next-generation sequencing for determination of intratumoral heterogeneity of canine osteosarcoma cell lines
Ayers, J., Milner, R. J., Cortés-Hinojosa, G., Riva, A., Axiak‐Bechtel, S. M., Sahay, B., Cascio, M., Lejeune, A. T., Shiomitsu, K., Souza, C. H. M., et al. (2021) · Journal of Veterinary Diagnostic Investigation · doi:10.1177/1040638720985242 · Cited by 18 · see citing works
miR-29a-3p mitigates the development of osteosarcoma through modulating IGF1 mediated PI3k/Akt/FOXO3 pathway by activating autophagy
Qi, S., Xu, L., Han, Y., Chen, H., & Cheng, A.-Y. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2078614 · Cited by 17 · see citing works
Exploration and validation of downregulated microRNA-199a-3p, downstream messenger RNA targets and transcriptional regulation in osteosarcoma.
Huang, W., Liu, A., Cai, K., He, R., Li, Z., Wei, Q., Chen, M., Huang, J., Yan, W., Zhou, H. H., et al. (2019) · Europe PMC (PubMed Central) · Cited by 15 · see citing works
Genome-editing approaches and applications: a brief review on CRISPR technology and its role in cancer
Siva, N., Gupta, S., Gupta, A., Shukla, J. N., Malik, B., & Shukla, N. (2021) · 3 Biotech · doi:10.1007/s13205-021-02680-4 · Cited by 14 · see citing works
Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)
Yu, T., Jiang, W., Wang, Y., Zhou, Y. Y., Jiao, J., & Wu, M. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5628 · Cited by 12 · see citing works
Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients
Zou, C., Huang, R., Lin, T., Wang, Y., Tu, J., Zhang, L., Wang, B., Huang, J., Zhao, Z., Xie, X., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1382276 · Cited by 11 · see citing works
Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma
Zvi, Y. S., Ugur, E., Batko, B. D., Gill, J. B., Roth, M. E., Gorlick, R. G., Hall, D. C., Tingling, J., Barkauskas, D. A., Zhang, J., et al. (2021) · Sarcoma · doi:10.1155/2021/8324348 · Cited by 11 · see citing works
Formononetin, J1 and J2 have different effects on endothelial cells via EWSAT1‐TRAF6 and its downstream pathway
Li, X., Huang, C., Sui, C. L., Liang, C. M., Qi, G. Y., Ren, Q. Y., Chen, J., & Huang, Z. Q. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14797 · Cited by 10 · see citing works
Implications of cancer stem cells in diabetes and pancreatic cancer
Mukherjee, A. G., Wanjari, U. R., Gopalakrishnan, A. V., Bradu, P., Sukumar, A., Patil, M., Renu, K., Dey, A., Vellingiri, B., George, A., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121211 · Cited by 8 · see citing works
Hormones as a double-edged sword: the role of hormones in cancer progression and the potential of targeted hormone therapies
Joshi, D., Patel, J., Munshi, M., Mistry, Z., Prajapati, A., Mukherjee, A., Ramachandran, A. V., Parashar, N. C., Parashar, G., Haque, S., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02517-z · Cited by 6 · see citing works
Identification and Functional Analysis of the Cell Proliferation Regulator, Insulin-like Growth Factor 1 (IGF1) in Freshwater Pearl Mussel (Hyriopsis cumingii)
Li, X., Feng, S., Wang, H., Shen, X., Chen, Y., Xuan, X., Fu, Y., Bai, Z., & Li, W. (2022) · Biology · doi:10.3390/biology11091369 · Cited by 5 · see citing works
Circ_0004674 regulation of glycolysis and proliferation mechanism of osteosarcoma through miR‐140‐3p/TCF4 pathway
Ma, Y., Du, S., Wang, S., Liu, X., Cong, L., Shen, W., & Ye, K. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23846 · Cited by 3 · see citing works
Establishment of A Nomogram for Predicting the Prognosis of Soft Tissue Sarcoma Based on Seven Glycolysis-Related Gene Risk Score
Liu, Y., Liu, C., Zhang, H., Yi, X., & Yu, A.-X. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.675865 · Cited by 2 · see citing works
Nanotechnology revolutionizing osteosarcoma treatment: Advances in targeted kinase inhibitors
Zhang, Y., Chao Hui, Z. H. O. U., Xie, Q., Xia, L., Li, Q., Liu, L., Lin, H., Xiong, X., Zhao, J., & Liang, W. (2025) · Nanotechnology Reviews · doi:10.1515/ntrev-2025-0147 · Cited by 1 · see citing works
Prognostic significance of biomarker expression on immunohistochemistry for overall survival in osteosarcoma: An overview of systematic reviews
Duddukunta, V. R., Chattopadhyay, A., Vathulya, M., & Dhingra, M. (2025) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2025.103264 · Cited by 1 · see citing works
Etiology of malign bone tumors
Aksu, N. (2019) · Demiroglu Science University Florence Nightingale Journal of Medicine · doi:10.5606/fng.btd.2019.021
Impact of Diabetes Mellitus Type 2 on Clinical Characteristics of Breast Cancer Patients
Siddiqui, M. H., Rana, M. A., Siddiqui, M. R. O., Iqbal, W., Elahi, R., Nawaz, Z., & Hafeez, M. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22167303
IGLC1 is an independent prognostic marker and potent therapeutic target in osteosarcoma
Wu, Z., Xie, X., Shi, G., Ning, K., & Zhao, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02653-6 · Cited by 1 · see citing works
Implication de la voie de signalisation Wnt/β-caténine dans le développement tumoral primaire et métastatique des ostéosarcomes
Danieau, G. (2019) · doi:10.70675/b658f08dz75d1z4bb2z8341zea788f7d17f6

Increased expression of insulin‐like growth factor‐1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma
Wang, Y., Han, X., Qiu, Y., Xiong, J., Yu, Y., Wang, B., Zhu, Z., Qian, B., Chen, Y., Wang, S., et al. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22077 · Cited by 83 · see citing works
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
Kuijjer, M. L., Peterse, E. F. P., van den Akker, B. E., Bruijn, I. H. B., Serra, M., Meza‐Zepeda, L. A., Myklebost, O., Hassan, A. B., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-245 · Cited by 95 · see citing works
CORR Insights®: Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-β as Involved in the Pathogenesis of Osteosarcoma
Peterse, E. F. P., & Bovée, J. V. M. G. (2015) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-015-4620-3 · Cited by 3 · see citing works
CORR Insights1: Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma
Peterse, E. F. P. (2016)
Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma
Burrow, S., Andrulis, I. L., Pollak, M., & Bell, R. S. (1998) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199809)69:1 · Cited by 115 · see citing works

Authors: Li, Y.-S., Liu, Q., He, H.-B., & Luo, W.
Affiliations: Central South University (CN)
Corresponding author: Luo, Wei
ORCID: Liu, Qing
Luo, Wei
Venue: Current Problems in Cancer
Publisher: Elsevier BV
Published: 2019-06
Volume: 43
Issue: 3
Pages: 228-235
ISSN: 0147-0272 (ISSN-L)
DOI: 10.1016/j.currproblcancer.2018.08.008
OpenAlex: W2891692865
Cited by: 35
References: 55
Citations by year: 2025: 3 · 2024: 5 · 2022: 5 · 2021: 10 · 2020: 6 · 2019: 6
FWCI: 0.85
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Current Problems in Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: National Natural Science Foundation of China (81874030, 81401838, 81402224)
Provincial Science Foundation of Hunan (2015JJ3139, 2017JJ3499)
Health and Family Planning Commission (B2014-12)
Administration of Traditional Chinese Medicine of Hunan Province (2015116)
Clinical and Rehabilitation Research Foundation
Weiming of Peking University (xywm2015II04, xywm2015II07)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
Keywords: osteosarcoma, insulin-like growth factor I, IGF-1 receptor, tumor progression, metastasis, chemoresistance, apoptosis, biomarkers, targeted therapy
MeSH terms: Antineoplastic Agents, Bone Neoplasms, Humans, Insulin-Like Growth Factor I, Prognosis, Osteosarcoma, Signal Transduction, Receptor, IGF Type 1, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The possible role of insulin-like growth factor-1 in osteosarcoma

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks